Next Article in Journal
Investigating p.Ala1035Val in NPC1: New Cellular Models for Niemann–Pick Type C Disease
Previous Article in Journal
Evaluation of Biochemical Characteristics and Performance of the 3 Screen ICA ELISA Kit
 
 
Review
Peer-Review Record

Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility

Int. J. Mol. Sci. 2024, 25(22), 12174; https://doi.org/10.3390/ijms252212174
by Maja Roman and Michał Nowicki *
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2024, 25(22), 12174; https://doi.org/10.3390/ijms252212174
Submission received: 7 October 2024 / Revised: 1 November 2024 / Accepted: 3 November 2024 / Published: 13 November 2024

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

To thank the authors for the excellent work as a narrative review of the detailed pathophysiology of MCD, emphasizing the dysfunction, inmune dysregulation and genetic susceptibility.

A clear, concise, separate manuscript on important aspects of the pathophysiology of this disease. 

Just give these suggestions for improving the manuscript:

-The text from line 127 to 129 is repeated in several paragraphs, please modify them.

-Line 129 to 131: What types of therapies are they ? add a comment on it

-Line 167 to 169: What types of immunomodulatory therapies are ? add a comment about it.

-In figure 1, the legend is missing, add it.

For the rest of the manuscript I have no further suggestions. 

Congratulations for the work

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

1. To improve the educational value of the paper, the incidence and prevalence of MCD should be presented.

2. Some content is repeated: lines 102-118 and lines 282-289. Please, correct.

3. The paragraph on the biomarkers should be moved before the paragraph on the treatment.

4. Line 153: Please, specify which study do you mean?

5. Line 202: Please, explain in more detail what is the connection between MCD and FSGS.

6. Line 219: avoid brand names of medicines (Myfortic).

7. The references should be cited in order of their appearance. Please, correct.

8. Figure 1 should be cited in the text.

9. Figure 1 is lacking the legend.

10. Tables should be cited in the text.

11. Some spaces are lacking, e.g.: line 39 (inchildren), line 40 (inadults), line 41 (suddenonset), line 44 (thatare), line 461 (geneenvironement)

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop